Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease (Q28241323)

Fibrosis associated with dopamine agonist therapy in Parkinson's disease

Europe PubMed Central

title

Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease (English)

0 references

1 reference

0 references

2

Werner Poewe

0 references

Angelo Antonini

series ordinal

1

object named as

Angelo Antonini

0 references

language of work or name

English

0 references

publication date

September 2007

0 references

published in

Lancet Neurology

0 references

volume

6

0 references

page(s)

826-9

0 references

issue

9

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

Tic reduction with pergolide in a randomized controlled trial in children

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

Dual dopamine agonist treatment in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

Dopamine agonists and the risk of cardiac-valve regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

Drugs and valvular heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970218-1

7 January 2021

10.1016/S1474-4422(07)70218-1

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

release_x4dbcjkvhnfe5audkh5dh5kyam

1281602

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/x4dbcjkvhnfe5audkh5dh5kyam

24 November 2022

mapped directly with Wikidata item

1281602

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference